http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105424828-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-027 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-02 |
| filingDate | 2015-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105424828-B |
| titleOfInvention | The method of enantiomter content in detection levocarnitine |
| abstract | The invention belongs to drug measurement techniques field, and in particular to a kind of method of enantiomter content in detection levocarnitine.The present invention is performed the derivatization as derivatization reagent by the use of benzoyl halogen series compound to levocarnitine, is then detected using HPLC, and the content of enantiomer is calculated with area normalization method.Enantiomter content in present invention detection levocarnitine, there is repeatability higher, preci-sion and accuracy, to controlling the quality of levocarnitine bulk drug, ensureing that drug safety is significant.In addition, the present invention uses benzoyl halogen series compound as derivatization reagent, cost is relatively low, TLC methods monitoring derivatization process shows, completely, levocarnitine and its enantiomter are completely converted into corresponding derivative to derivative reaction, so as to ensure that the accurate of testing result. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2740535-C1 |
| priorityDate | 2015-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 35.